Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Aripiprazole Intramuscular Depot in the Acute Treatment of Adults With Schizophrenia

NCT03172871 is registered in ClinicalTrials.gov with Otsuka Beijing Research Institute as lead sponsor.

NCT NCT03172871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03172871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Aripiprazole Intramuscular Depot in the Acute Treatment of Adults With Schizophrenia
Lead sponsor
Otsuka Beijing Research Institute
Phase
Phase 3
Overall status
Completed
Start date
May 15, 2017
Completion date
September 30, 2019
Enrollment
436 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia